Development of next generation drugs for chronic myeloid leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1060225

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $632,726.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Structural Biology (incl. Macromolecular Modelling)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

leukaemia | peptide synthesis | peptides | structural biology | structure-based drug design

Related Links